Cellectar Biosciences, Inc. (CLRB) financial statements (2020 and earlier)

Company profile

Business Address 100 CAMPUS DRIVE
FLORHAM PARK, NJ 07932
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1313101149
Cash and cash equivalents1313101149
Restricted cash and investments     0
Other undisclosed current assets111100
Total current assets:15141112410
Noncurrent Assets
Operating lease, right-of-use asset0
Property, plant and equipment010122
Long-term investments and receivables01    
Long-term investments01    
Intangible assets, net (including goodwill)  2222
Goodwill  2222
Other noncurrent assets000000
Total noncurrent assets:112334
TOTAL ASSETS:16151315813
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:322111
Accounts payable 1    
Accrued liabilities 0    
Employee-related liabilities 0    
Other undisclosed accounts payable and accrued liabilities302111
Debt000000
Deferred rent credit 0
Derivative instruments and hedges, liabilities 00051
Deferred revenue and credits0   
Total current liabilities:322262
Noncurrent Liabilities
Long-term debt and lease obligation0 0000
Long-term debt, excluding current maturities    00
Capital lease obligations 0000
Operating lease, liability0
Liabilities, other than long-term debt 0 000
Deferred revenue and credits 000
Deferred rent credit 0
Total noncurrent liabilities:000000
Total liabilities:322263
Stockholders' equity
Stockholders' equity attributable to parent, including:12131114211
Preferred stock   1  
Common stock000000
Additional paid in capital11910894836670
Accumulated deficit(108)(98)(84)(71)(65)(59)
Other undisclosed stockholders' equity attributable to parent131   
Total stockholders' equity:12131114211
TOTAL LIABILITIES AND EQUITY:16151315813

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:(0)(0)  (0)(0)
Operating expenses(15)(13)(14)(9)(9)(10)
Operating loss:(15)(13)(14)(9)(9)(10)
Nonoperating income000332
Investment income, nonoperating000342
Interest and debt expense   (0)(0)(0)
Loss from continuing operations before income taxes:(15)(13)(14)(6)(5)(8)
Income tax benefit     3
Net loss:(15)(13)(14)(6)(5)(5)
Other undisclosed net income (loss) attributable to parent   00(3)
Net loss attributable to parent:(15)(13)(14)(6)(5)(8)
Preferred stock dividends and other adjustments (2)(1)   
Net loss available to common stockholders, diluted:(15)(15)(15)(6)(5)(8)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(15)(13)(14)(6)(5)(5)
Comprehensive loss, net of tax, attributable to parent:(15)(13)(14)(6)(5)(5)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: